𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rituximab in cutaneous B-cell lymphoma: a report of two cases

✍ Scribed by R.A. Sabroe; F.J. Child; A.J. Woolford; M.F. Spittle; R. Russell-Jones

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
416 KB
Volume
143
Category
Article
ISSN
0007-0963

No coin nor oath required. For personal study only.

✦ Synopsis

We report two patients with primary cutaneous B-cell lymphoma who were treated with rituximab, a new anti-CD20 monoclonal antibody. The first patient, who had a diffuse large B-cell lymphoma of the lower leg, achieved an 85% improvement. The second patient, who had a primary cutaneous B-cell lymphoma, which had undergone high-grade transformation and systemic spread, achieved a minor response of approximately 30%. Both patients subsequently relapsed. The first patient achieved complete clearance with a second course of rituximab given with systemic chemotherapy, but again relapsed. Treatment with rituximab has been reported to produce response rates of 48% in relapsed systemic low-grade or follicular lymphoma, but there are no previous reports of the use of rituximab in primary cutaneous B-cell lymphoma.

πŸ“œ SIMILAR VOLUMES

Management of neurotropic low-grade B-ce
Management of neurotropic low-grade B-cell lymphoma: Report of two cases
✍ Allie Garcia-Serra; Nancy Price Mendenhall; Russell W. Hinerman; James W. Lynch πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 225 KB

## Background: Low-grade lymphomas do not commonly involve the central or peripheral nervous system. ## Methods: Case report and review of the literature of two cases of b-cell lymphoma of the extranodal marginal zone type involving the head and neck region with evidence of extensive neurotropism

ALK-positive diffuse large B-cell lympho
ALK-positive diffuse large B-cell lymphoma: report of three cases
✍ Hyoun Wook Lee; Kihyun Kim; Wonseog Kim; Young Hyeh Ko πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 318 KB

## Abstract Diffuse large B‐cell lymphoma positive for anaplastic lymphoma kinase (ALK^+^ DLBCL) is a rare variant of diffuse large B‐cell lymphoma, with characteristic morphological, immunohistochemical and cytogenetic features. Only 34 cases of ALK‐positive diffuse large B‐cell lymphoma have so f